Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature

• Publication date

  2011-03-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature09779PMID 21368834
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phosphorylation of Mcl‐1 by CDK1–cyclin B1 initiates its Cdc20‐dependent destruction during mitotic arrest

  2010cited by this paper
• Cyclin-Dependent Kinase 1-Mediated Bcl-xL/Bcl-2 Phosphorylation Acts as a Functional Link Coupling Mitotic Arrest and Apoptosis

  2009cited by this paper
• RING domain E3 ubiquitin ligases.

  2009cited by this paper
• Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.

  2009cited by this paper
• Recognition and processing of ubiquitin-protein conjugates by the proteasome.

  2009cited by this paper
• (Un)expected roles of c-IAPs in apoptotic and NFκB signaling pathways

  2008cited by this paper
• The BCL-2 protein family: opposing activities that mediate cell death

  2008cited by this paper
• FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation

  2008cited by this paper
• Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs.

  2008cited by this paper
• (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways.

  2008cited by this paper
• Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy

  2008cited by this paper
• Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer

  2008cited by this paper
• Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak

  2007cited by this paper
• Targeted anti-mitotic therapies: can we improve on tubulin agents?

  2007cited by this paper
• The reversibility of mitotic exit in vertebrate cells

  2006cited by this paper
• No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

  2005cited by this paper
• Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

  2005cited by this paper
• Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis.

  2005cited by this paper
• Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint.

  2004cited by this paper
• MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

  2004cited by this paper
• Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies.

  2002cited by this paper
• A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B.

  1995cited by this paper

• Biological clocks keep a watch on mitosis

  2026cites this paper
• Mitotic errors as triggers of cell death and inflammation

  2026cites this paper
• Screening a living biobank identifies cabazitaxel as a strategy to combat acquired taxol resistance in high-grade serous ovarian cancer

  2025cites this paper
• Maritoclax Overcomes FBW7 Deficiency‐Driven Irinotecan Resistance in Colorectal Cancer by Targeting MCL1

  2025cites this paper
• Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-XL degradation to overcome cancer chemoresistance

  2025cites this paper
• Aurora B inhibition induces hyper-polyploidy and loss of long-term proliferative potential in RB and p53 defective cells

  2025influential citation
• De novo discovery of a molecular glue–like macrocyclic peptide that induces MCL1 homodimerization

  2025cites this paper
• Recent advances of small-molecule Mcl-1 inhibitors or degraders as promising anti-cancer agents (2018-present).

  2025cites this paper
• A Comprehensive Insight into Apoptosis: Molecular Mechanisms, Signaling Pathways, and Modulating Therapeutics

  2025cites this paper
• Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy.

  2025cites this paper
• The E3 ubiquitin ligase SPRYD3-MYCBP2(PAM) regulates mitotic cell fate and ubiquitination of USP11 to control spindle assembly

  2025cites this paper
• Targeting myeloid cell leukemia-1 protein to identify potential compounds for chronic myeloid leukemia treatment: Molecular docking and molecular dynamics simulation approaches.

  2025cites this paper
• The FBXO45–GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis

  2025cites this paper
• Top 100 most-cited articles on apoptosis of non-small cell lung cancer over the past two decades: a bibliometrics analysis

  2025cites this paper
• Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft Model

  2025cites this paper
• Polyploid giant cancer cells: A novel target in future cancer therapy.

  2025cites this paper
• Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities

  2025cites this paper
• MicroRNAs as the critical regulators of ubiquitin-proteasome system through F-box protein targeting during tumor progression

  2025cites this paper
• Mcl‐1 is a Gatekeeper Molecule to Regulate the Crosstalk Between Ferroptotic Agent‐Induced ER Stress and TRAIL‐Induced Apoptosis

  2025cites this paper
• Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy

  2025cites this paper
• Cancer-specific dual-factor cascade recognition fluorescent probe for imaging and tumor diagnosis.

  2025cites this paper
• Phosphodegrons in Health and Disease: From Cellular Homeostasis to Therapeutic Potential

  2025cites this paper
• Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma

  2025cites this paper
• MCL1 may not mediate chemoresistance

  2025cites this paper
• Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q.

  2025cites this paper
• Interventionally-guided representation learning for robust and interpretable AI models in cancer medicine

  2025cites this paper
• CDKN1B (p27/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors

  2024cites this paper
• Skp2: A critical molecule for ubiquitination and its role in cancer.

  2024cites this paper
• Aurora B inhibition promotes a hyper-polyploid state and continued endomitotic cycles in RB and p53 defective cells

  2024cites this paper
• PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer

  2024cites this paper
• Characterization of polyploidy in cancer: Current status and future perspectives.

  2024cites this paper
• BCL-XL–targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors

  2024cites this paper
• PHLDA1 protects intestinal barrier function via restricting intestinal epithelial cells apoptosis in inflammatory bowel disease.

  2024cites this paper
• MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC

  2024cites this paper
• The PROTAC selectively degrading BCL-XL inhibits the growth of tumors and significantly synergizes with Paclitaxel.

  2024cites this paper
• A biomarker exploration in small-cell lung cancer for brain metastases risk and prophylactic cranial irradiation therapy efficacy.

  2024cites this paper
• Polyploidy as an outcome of anticancer therapies and a contributing cause of their lack of efficacy

  2024cites this paper
• Small molecule Mcl-1 inhibitor for triple negative breast cancer therapy

  2024cites this paper
• Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase.

  2024cites this paper
• Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors

  2024cites this paper
• Roles of DEPDC1 in various types of cancer (Review)

  2024cites this paper
• Centrosome amplification primes ovarian cancer cells for apoptosis and potentiates the response to chemotherapy

  2024cites this paper
• A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.

  2024cites this paper
• Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review

  2024cites this paper
• The HTLV-I oncoprotein Tax inactivates the tumor suppressor FBXW7

  2024cites this paper
• Polyploid giant cancer cells: origin, possible pathways of formation, characteristics, and mechanisms of regulation

  2024cites this paper
• Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options

  2024cites this paper
• Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors

  2024cites this paper
• Recent advances on two-dimensional material-based nanosystems for gene delivery

  2024cites this paper
• Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer

  2024cites this paper
• Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer

  2024cites this paper
• Discovery of Phenylpyrazole Derivatives as a New Class of Selective Inhibitors of MCL-1 with Antitumor Activity

  2024cites this paper
• Targeting MCL-1 triggers DNA damage and an anti-proliferative response independent from apoptosis induction

  2023cites this paper
• Podophyllotoxin reduces the aggressiveness of human oral squamous cell carcinoma through myeloid cell leukemia-1

  2023cites this paper
• Cancer‐associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7

  2023cites this paper
• Centrosome amplification primes for apoptosis and favors the response to chemotherapy in ovarian cancer beyond multipolar divisions

  2023cites this paper
• Regulation and role of the PP2A-B56 holoenzyme family in cancer.

  2023cites this paper
• Long Noncoding RNAs in Taxane Resistance of Breast Cancer

  2023cites this paper
• A Review of Reagents for Fluorescence Microscopy of Cellular Compartments and Structures, Part I: BacMam Labeling and Reagents for Vesicular Structures

  2023cites this paper
• Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors

  2023cites this paper
• Targeting MCL-1 protein to treat cancer: opportunities and challenges

  2023cites this paper
• TUBA1A licenses APC/C‐mediated mitotic progression to drive glioblastoma growth by inhibiting PLK3

  2023cites this paper
• Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins

  2023cites this paper
• FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2

  2023cites this paper
• E3 Ubiquitin Ligase TRIP12 Controls Exit from Mitosis via Positive Regulation of MCL-1 in Response to Taxol

  2023influential citation
• Molecular modeling study of pyrrolidine derivatives as novel myeloid cell leukemia-1 inhibitors through combined 3D-QSAR, molecular docking, ADME/Tox and MD simulation techniques

  2023cites this paper
• Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.

  2023cites this paper
• Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

  2023cites this paper
• Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients

  2023cites this paper
• CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo

  2023cites this paper
• Protein Levels of Anti-Apoptotic Mcl-1 and the Deubiquitinase USP9x Are Cooperatively Upregulated during Prostate Cancer Progression and Limit Response of Prostate Cancer Cells to Radiotherapy

  2023cites this paper
• Bilateral and synchronous male breast cancer: a case report.

  2023cites this paper
• FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies

  2023cites this paper
• FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1

  2023cites this paper
• Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers

  2023cites this paper
• Enabling, Decagram-Scale Synthesis of Macrocyclic MCL-1 Inhibitor ABBV-467.

  2023cites this paper
• 1 Design , Synthesis and Biological Evaluation of 6-Substituted Thieno [ 3 , 2-d ] pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors

  2022cites this paper
• Concomitant inhibition of FLT3 and MCL-1 in FLT3 mutated Acute Myeloid Leukemia

  2022cites this paper
• Apoptosis as a Barrier against CIN and Aneuploidy

  2022cites this paper
• The SCF–FBXW7 E3 ubiquitin ligase triggers degradation of histone 3 lysine 4 methyltransferase complex component WDR5 to prevent mitotic slippage

  2022influential citation
• 1 Design , Synthesis , in Vitro and in Vivo Biological Evaluation of 2-Amino-3-Aroylbenzo [ b ] furan Derivatives as Highly Potent Tubulin Polymerization Inhibitors

  2022cites this paper
• E3 ubiquitin ligases in the acute leukemic signaling pathways

  2022cites this paper
• FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer

  2022cites this paper
• FBXW7 triggers degradation of WDR5 to prevent mitotic slippage

  2022influential citation
• Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer.

  2022cites this paper
• Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins

  2022cites this paper
• NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.

  2022cites this paper
• Tanshinone IIA Accomplished Protection against Radiation-Induced Cardiomyocyte Injury by Regulating the p38/p53 Pathway

  2022cites this paper
• Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancer

  2022cites this paper
• Discovery of a New Mcl‐1 Protein Inhibitor through the QSAR Approach and Molecular Docking Study

  2022cites this paper
• Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia

  2022cites this paper
• Activation of the integrated stress response is a vulnerability for multidrug‐resistant FBXW7‐deficient cells

  2022influential citation
• Deubiquitinases in cell death and inflammation

  2022cites this paper
• Bcl-xL activity influences outcome of the mitotic arrest

  2022cites this paper
• Recent Developments in the Synthesis and Anticancer Activity of Indole and its Derivatives.

  2022cites this paper
• Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma.

  2022cites this paper
• UBXD8 mediates mitochondria‐associated degradation to restrain apoptosis and mitophagy

  2022cites this paper
• Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial

  2022cites this paper
• Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer

  2022cites this paper
• PHLPP1 deficiency ameliorates cardiomyocyte death and cardiac dysfunction through inhibiting Mcl-1 degradation.

  2022cites this paper